Sunitinib official instructions: dosage, suitable populations and precautions

Sunitinib is a multi-target tyrosine kinase inhibitor (TKI) that is mainly used to treat several specific types of cancer, including advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumors (pNET). Its mechanism of action inhibits tumor cells by inhibiting a variety of tyrosine kinases to prevent tumor growth and metastasis.

1. In terms of indications,

Advanced renal cell carcinoma refers to kidney cancer that has metastasized or cannot be completely removed. Such patients often do not respond well to standard treatments, and sunitinib, as a targeted therapy, provides a new treatment option for these patients. For gastrointestinal stromal tumors (GIST), sunitinib is indicated for patients whose disease has progressed despite other treatments. For pancreatic neuroendocrine tumors, sunitinib is often used in patients who show signs of metastasis or recurrence.

2. In terms of usage and dosage,

The usual starting dose of sunitinib is 50mg taken orally daily, and a treatment plan of 4 weeks of taking and 2 weeks of rest (i.e. 4/2 regimen) is adopted, that is, after taking it for four weeks in one cycle, it is stopped for two weeks. In addition, there is another way of use, which is to take 37.5mg orally daily without rest. The choice between these two usages depends on the patient's specific situation and the doctor's judgment.

3. In terms of side effects,

While taking sunitinib, patients need regular monitoring to evaluate the drug's efficacy and side effects. The most common side effects include fatigue, high blood pressure, diarrhea, rash, and oral mucositis. During treatment, doctors will adjust dosage based on patient tolerance and clinical response. For example, if a patient experiences significant side effects, the dose may need to be reduced or the drug temporarily discontinued. In the early stages of treatment, due to the effects of drugs on the blood system, patients should have regular blood tests to monitor the levels of white blood cells and platelets to avoid the risk of infection or bleeding due to low blood cells.

In addition, patients also need to pay attention to diet and lifestyle adjustments while taking sunitinib. Because high blood pressure is a common side effect of sunitinib, patients need to monitor changes in blood pressure and talk to their doctor about ways to control high blood pressure. At the same time, maintaining a healthy diet and moderate exercise can help improve patients' quality of life and reduce the occurrence of side effects.

Before starting treatment with sunitinib, patients should also tell their doctor about their past medical history, including any history of heart disease, high blood pressure, liver disease, or other serious conditions. In addition, pregnant and breastfeeding women should avoid using this drug because its safety to the fetus or infant has not been established.

In summary, sunitinib, as an effective anti-tumor drug, provides new treatment hope for patients with a variety of advanced cancers. Its multi-target mechanism of action enables it to effectively inhibit the growth and spread of tumor cells. However, during use, patients need to pay close attention to physical changes, conduct regular medical monitoring, and reasonably adjust medication under the guidance of a doctor to ensure the safety and effectiveness of treatment. In the future, as research continues to deepen, the scope of application and therapeutic effect of sunitinib are expected to be further improved, bringing good news to more cancer patients.

Reference materials:https://www.sutent.com/